Prof Bogda Koczwara
@bogda-koczwara.bsky.social
Mother, wife, runner | Oncologist researching #survivorship Director, Australian Research Centre for Cancer Survivorship|
April is Youth Cancer Awareness Month.
Younger people face unique challenges when it comes to cancer that are often inadequately addressed. And the rates of early onset cancers are rising.
But there is much to be done! And we can do it!
Younger people face unique challenges when it comes to cancer that are often inadequately addressed. And the rates of early onset cancers are rising.
But there is much to be done! And we can do it!
April 4, 2025 at 8:04 PM
April is Youth Cancer Awareness Month.
Younger people face unique challenges when it comes to cancer that are often inadequately addressed. And the rates of early onset cancers are rising.
But there is much to be done! And we can do it!
Younger people face unique challenges when it comes to cancer that are often inadequately addressed. And the rates of early onset cancers are rising.
But there is much to be done! And we can do it!
Look what arrived today!
March 19, 2025 at 12:08 AM
Look what arrived today!
👇👇study of women with obesity related cancers vs controls.
- ⬆️risk of mortality with more CVD abnormalities for cases and controls
-CVD abnormalities NOT associated with ⬆️all‐ cause mortality risk in those receiving cardiotoxic treatment.
tinyurl.com/2p2afxzr
- ⬆️risk of mortality with more CVD abnormalities for cases and controls
-CVD abnormalities NOT associated with ⬆️all‐ cause mortality risk in those receiving cardiotoxic treatment.
tinyurl.com/2p2afxzr
The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer - PubMed
Preexisting cardiovascular abnormalities are an important predictor of adverse health outcomes among women with and without cancer in the WHI.
tinyurl.com
March 16, 2025 at 11:03 PM
👇👇study of women with obesity related cancers vs controls.
- ⬆️risk of mortality with more CVD abnormalities for cases and controls
-CVD abnormalities NOT associated with ⬆️all‐ cause mortality risk in those receiving cardiotoxic treatment.
tinyurl.com/2p2afxzr
- ⬆️risk of mortality with more CVD abnormalities for cases and controls
-CVD abnormalities NOT associated with ⬆️all‐ cause mortality risk in those receiving cardiotoxic treatment.
tinyurl.com/2p2afxzr
🌟Share your insights on strategies for implementing PROMs in clinical practice - participate in 4 online survey rounds (15-20 mins each)
Sign up now at ugent.qualtrics.com/jfe/form/SV_...
Your input is invaluable in improving patient outcomes. 💪
Sign up now at ugent.qualtrics.com/jfe/form/SV_...
Your input is invaluable in improving patient outcomes. 💪
Qualtrics Survey | Qualtrics Experience Management
The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.
ugent.qualtrics.com
March 16, 2025 at 1:29 AM
🌟Share your insights on strategies for implementing PROMs in clinical practice - participate in 4 online survey rounds (15-20 mins each)
Sign up now at ugent.qualtrics.com/jfe/form/SV_...
Your input is invaluable in improving patient outcomes. 💪
Sign up now at ugent.qualtrics.com/jfe/form/SV_...
Your input is invaluable in improving patient outcomes. 💪
Our paper on experiences of managing lymphoedema risk after cancer is out highlighting main barriers and potential solutions. See tinyurl.com/yc4xaz4k
March 14, 2025 at 7:41 PM
Our paper on experiences of managing lymphoedema risk after cancer is out highlighting main barriers and potential solutions. See tinyurl.com/yc4xaz4k
Reposted by Prof Bogda Koczwara
NEW PODCAST: Fear of cancer recurrence is a major concern for survivors—how can we better support them?
Hosted by @bogda-koczwara.bsky.social with Prof Sophie Lebel + A/Prof Ben Smith
🔗 Listen now: t.ly/L5qvM
#CancerSurvivorship #FearOfCancerRecurrence #FCR #OncologyCare #CanSky #OncSky #MedSky
Hosted by @bogda-koczwara.bsky.social with Prof Sophie Lebel + A/Prof Ben Smith
🔗 Listen now: t.ly/L5qvM
#CancerSurvivorship #FearOfCancerRecurrence #FCR #OncologyCare #CanSky #OncSky #MedSky
February 20, 2025 at 1:30 AM
NEW PODCAST: Fear of cancer recurrence is a major concern for survivors—how can we better support them?
Hosted by @bogda-koczwara.bsky.social with Prof Sophie Lebel + A/Prof Ben Smith
🔗 Listen now: t.ly/L5qvM
#CancerSurvivorship #FearOfCancerRecurrence #FCR #OncologyCare #CanSky #OncSky #MedSky
Hosted by @bogda-koczwara.bsky.social with Prof Sophie Lebel + A/Prof Ben Smith
🔗 Listen now: t.ly/L5qvM
#CancerSurvivorship #FearOfCancerRecurrence #FCR #OncologyCare #CanSky #OncSky #MedSky
February 18, 2025 at 7:58 PM
I am humbled and honoured to be appointed as the inaugural Director of the Australian Research Centre for Cancer Survivorship. There is so much we can do! tinyurl.com/yp8857r6
International cancer expert to lead Australia's first survivorship research centre
Professor Bogda Koczwara AM will drive innovation at UNSW Sydney and Cancer Council NSW’s Australian Research Centre for Cancer Survivorship.
tinyurl.com
February 13, 2025 at 10:14 PM
I am humbled and honoured to be appointed as the inaugural Director of the Australian Research Centre for Cancer Survivorship. There is so much we can do! tinyurl.com/yp8857r6
This World Cancer Day I think of all the patients whose journeys I shared over the past 30 years (yes, 30). This photo of one of my patients, who in between chemotherapies found time to be a clown doctor brings back so many emotions. Never forgotten!
February 4, 2025 at 10:38 AM
This World Cancer Day I think of all the patients whose journeys I shared over the past 30 years (yes, 30). This photo of one of my patients, who in between chemotherapies found time to be a clown doctor brings back so many emotions. Never forgotten!
Must read 👇👇👇
"diagnosis of cancer marks the beginning of two fights: one against the disease and the other against financial ruin. Sadly, the term financial toxicity connotes benignity in its clinical detachment"
tinyurl.com/2asbwv9k
"diagnosis of cancer marks the beginning of two fights: one against the disease and the other against financial ruin. Sadly, the term financial toxicity connotes benignity in its clinical detachment"
tinyurl.com/2asbwv9k
Business of Health Care and the Personal Cost of Cancer Care | JCO Oncology Practice
tinyurl.com
January 27, 2025 at 6:57 PM
Must read 👇👇👇
"diagnosis of cancer marks the beginning of two fights: one against the disease and the other against financial ruin. Sadly, the term financial toxicity connotes benignity in its clinical detachment"
tinyurl.com/2asbwv9k
"diagnosis of cancer marks the beginning of two fights: one against the disease and the other against financial ruin. Sadly, the term financial toxicity connotes benignity in its clinical detachment"
tinyurl.com/2asbwv9k
A case-control study showing an association between CVD and advanced stage of breast cancer at diagnosis, independent of delayed diagnosis and shared risk.
Time to focus on the crosstalk between CVD and cancer!
jamanetwork.com/journals/jam...
Time to focus on the crosstalk between CVD and cancer!
jamanetwork.com/journals/jam...
January 14, 2025 at 12:18 AM
A case-control study showing an association between CVD and advanced stage of breast cancer at diagnosis, independent of delayed diagnosis and shared risk.
Time to focus on the crosstalk between CVD and cancer!
jamanetwork.com/journals/jam...
Time to focus on the crosstalk between CVD and cancer!
jamanetwork.com/journals/jam...
A new dawn to mark the start of 2025. Happy New Year friends!
January 1, 2025 at 3:18 PM
A new dawn to mark the start of 2025. Happy New Year friends!
Reposted by Prof Bogda Koczwara
Amazing paper in @thelancet.bsky.social evidencing something we argue in #publichealth the whole time: the opportunity cost of increasingly expensive medications
'During 2000–20, NHS coverage of new drugs displaced more population health than it generated.'
www.thelancet.com/journals/lan...
'During 2000–20, NHS coverage of new drugs displaced more population health than it generated.'
www.thelancet.com/journals/lan...
Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis
During 2000–20, NHS coverage of new drugs displaced more population health than it generated. Our results highlight the inherent trade-offs between individuals who directly benefit from new drugs and those who forgo health due to the reallocation of resources towards new drugs.
www.thelancet.com
December 16, 2024 at 2:09 PM
Amazing paper in @thelancet.bsky.social evidencing something we argue in #publichealth the whole time: the opportunity cost of increasingly expensive medications
'During 2000–20, NHS coverage of new drugs displaced more population health than it generated.'
www.thelancet.com/journals/lan...
'During 2000–20, NHS coverage of new drugs displaced more population health than it generated.'
www.thelancet.com/journals/lan...
Reposted by Prof Bogda Koczwara
On the commercial-political-emotional success of the alternative, evidence-free wellness movement:
"You can look like us, feel like us, their chorus goes, if you follow our rules and purchase our powders"
from @elainegodfrey.bsky.social
www.theatlantic.com/politics/arc...
"You can look like us, feel like us, their chorus goes, if you follow our rules and purchase our powders"
from @elainegodfrey.bsky.social
www.theatlantic.com/politics/arc...
The Wellness Women Are on the March
Behind MAHA, RFK Jr.’s alternative-health movement, is a legion of Instagram influencers with millions of followers.
www.theatlantic.com
December 15, 2024 at 9:46 AM
On the commercial-political-emotional success of the alternative, evidence-free wellness movement:
"You can look like us, feel like us, their chorus goes, if you follow our rules and purchase our powders"
from @elainegodfrey.bsky.social
www.theatlantic.com/politics/arc...
"You can look like us, feel like us, their chorus goes, if you follow our rules and purchase our powders"
from @elainegodfrey.bsky.social
www.theatlantic.com/politics/arc...
Hot of the press from @proteuspros - an infographic explaining the value of PROs!
Note - they need to start as parr of the clinical encounter to benefit patients and society.
tinyurl.com/3m594fhk
Note - they need to start as parr of the clinical encounter to benefit patients and society.
tinyurl.com/3m594fhk
December 13, 2024 at 6:24 PM
Hot of the press from @proteuspros - an infographic explaining the value of PROs!
Note - they need to start as parr of the clinical encounter to benefit patients and society.
tinyurl.com/3m594fhk
Note - they need to start as parr of the clinical encounter to benefit patients and society.
tinyurl.com/3m594fhk
Reposted by Prof Bogda Koczwara
Two weeks until the #MASCC25 Conference Scholarship deadline on December 18!
All other abstracts (including other award/scholarship applications) are due by January 8, 2025.
mascc.org/annualmeetin...
#SuppOnc #SurvOnc #GlobOnc #PallOnc #Oncology @oncoalert.bsky.social
All other abstracts (including other award/scholarship applications) are due by January 8, 2025.
mascc.org/annualmeetin...
#SuppOnc #SurvOnc #GlobOnc #PallOnc #Oncology @oncoalert.bsky.social
December 4, 2024 at 7:07 PM
Two weeks until the #MASCC25 Conference Scholarship deadline on December 18!
All other abstracts (including other award/scholarship applications) are due by January 8, 2025.
mascc.org/annualmeetin...
#SuppOnc #SurvOnc #GlobOnc #PallOnc #Oncology @oncoalert.bsky.social
All other abstracts (including other award/scholarship applications) are due by January 8, 2025.
mascc.org/annualmeetin...
#SuppOnc #SurvOnc #GlobOnc #PallOnc #Oncology @oncoalert.bsky.social
Reposted by Prof Bogda Koczwara
I hope you get a chance to look after yourself soon Eric. And by extension, the patients 🤗🙏
www.bmj.com/content/364/...
www.bmj.com/content/364/...
Looking after ourselves at work: the importance of being hydrated and fed
Hospitals should remove any barriers to doctors eating and drinking during the working day
As healthcare providers, it’s easy to forget to look after ourselves at work. We know that taking breaks and...
www.bmj.com
December 5, 2024 at 8:26 AM
I hope you get a chance to look after yourself soon Eric. And by extension, the patients 🤗🙏
www.bmj.com/content/364/...
www.bmj.com/content/364/...
If there is only one thing you will read today - make it this one! So many lessons on how to care:
-illuminate the personhood
-understand life outside the hospital
-practical compassion
-sit with darkness
tinyurl.com/4h2u476m
-illuminate the personhood
-understand life outside the hospital
-practical compassion
-sit with darkness
tinyurl.com/4h2u476m
The Care That Saved Me | NEJM
When a pediatric psychologist’s young child becomes seriously ill, she learns unsought lessons about better ways of caring for children and their caregivers in devastating circumstances.
tinyurl.com
December 6, 2024 at 2:26 AM
If there is only one thing you will read today - make it this one! So many lessons on how to care:
-illuminate the personhood
-understand life outside the hospital
-practical compassion
-sit with darkness
tinyurl.com/4h2u476m
-illuminate the personhood
-understand life outside the hospital
-practical compassion
-sit with darkness
tinyurl.com/4h2u476m
Reposted by Prof Bogda Koczwara
December 1, 2024 at 12:04 PM
Reposted by Prof Bogda Koczwara
SONIA trial - Pts with ER+ breast cancer beginning treatment in the metastatic setting randomized to 1st line vs 2nd line use of CDK4/6 inhibitor (+ endocrine therapy). No sig difference in PFS.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature
The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
www.nature.com
November 29, 2024 at 6:16 PM
SONIA trial - Pts with ER+ breast cancer beginning treatment in the metastatic setting randomized to 1st line vs 2nd line use of CDK4/6 inhibitor (+ endocrine therapy). No sig difference in PFS.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Prof Bogda Koczwara
Very good to see more de-escalation trials publishing in HER2 positive early breast cancer. Here the HELEN-006 trial. www.thelancet.com/journals/lan...
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006)...
These findings might suggest a potential advantage of nab-paclitaxel combined with
trastuzumab and pertuzumab compared with the standard regimen in neoadjuvant therapy
for patients with HER2-positive ...
www.thelancet.com
November 29, 2024 at 7:48 AM
Very good to see more de-escalation trials publishing in HER2 positive early breast cancer. Here the HELEN-006 trial. www.thelancet.com/journals/lan...
Reposted by Prof Bogda Koczwara
This is how we should be doing Oncology trials - the Dutch SONIA trial looking at treatment sequencing of CDK 4/6 inhibitors in advanced breast cancer. A self funding efficiency trial! #oncsky www.nature.com/articles/s41...
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature
The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
www.nature.com
November 27, 2024 at 7:24 PM
This is how we should be doing Oncology trials - the Dutch SONIA trial looking at treatment sequencing of CDK 4/6 inhibitors in advanced breast cancer. A self funding efficiency trial! #oncsky www.nature.com/articles/s41...
Reposted by Prof Bogda Koczwara
Cervical cancer mortality in US women younger than 25 years significantly declined between 2016 and 2021, likely due to the widespread adoption of HPV vaccination.
ja.ma/4i9ghPC
ja.ma/4i9ghPC
November 28, 2024 at 12:37 AM
Cervical cancer mortality in US women younger than 25 years significantly declined between 2016 and 2021, likely due to the widespread adoption of HPV vaccination.
ja.ma/4i9ghPC
ja.ma/4i9ghPC
Improved survival with neoadjuvant therapy for #TNBC KEYNOTE-522
at med follow-up of 75.1 mo 60 mo OS: 86.6% for pembro-chemo vs 81.7% placebo-chemo
tinyurl.com/nhb7ze3v
at med follow-up of 75.1 mo 60 mo OS: 86.6% for pembro-chemo vs 81.7% placebo-chemo
tinyurl.com/nhb7ze3v
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | NEJM
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522
trial showed significant improvements in pathological complete response and event-free
survival with the addition...
tinyurl.com
November 28, 2024 at 3:09 AM
Improved survival with neoadjuvant therapy for #TNBC KEYNOTE-522
at med follow-up of 75.1 mo 60 mo OS: 86.6% for pembro-chemo vs 81.7% placebo-chemo
tinyurl.com/nhb7ze3v
at med follow-up of 75.1 mo 60 mo OS: 86.6% for pembro-chemo vs 81.7% placebo-chemo
tinyurl.com/nhb7ze3v
Reposted by Prof Bogda Koczwara
Grade 1-2 treatment-related irAEs in the first cycle of therapy were associated with longer overall survival compared to no irAEs from checkpoint inhibitors. #survonc #supponc
doi.org/10.1093/jnci...
doi.org/10.1093/jnci...
First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors
AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate
doi.org
November 27, 2024 at 9:46 PM
Grade 1-2 treatment-related irAEs in the first cycle of therapy were associated with longer overall survival compared to no irAEs from checkpoint inhibitors. #survonc #supponc
doi.org/10.1093/jnci...
doi.org/10.1093/jnci...